Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

This study has been terminated.
(Sponsor decision)
Information provided by (Responsible Party):
Amgen Identifier:
First received: September 10, 2012
Last updated: August 6, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: August 2015
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: April 1, 2015